Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla. , Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a biotechnology company focused on the discovery, development and
Toggle Summary KemPharm Reports Third Quarter 2022 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022 , at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmission Advancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022
Toggle Summary KemPharm to Report Third Quarter 2022 Financial Results
CELEBRATION, Fla. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference
Toggle Summary KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
CELEBRATION, Fla. , Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, announced its support for Niemann-Pick Awareness Month,
Toggle Summary KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla. , Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel
Toggle Summary KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CELEBRATION, Fla. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022 , at 5:00 p.m. ET Perry Sternberg , Corium, Inc.’s President and CEO, to Participate and Provide Update on the Commercialization of AZSTARYS ® Acquired substantially all the assets and operations of
Toggle Summary KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
CELEBRATION, Fla. , Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm to Report Second Quarter 2022 Financial Results
CELEBRATION, Fla. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and
Toggle Summary KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
CELEBRATION, Fla. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) ( KemPharm , or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and